Home
    Disclaimer
    Lormetazepam molecular structure

    Lormetazepam Stats & Data

    Noctamid
    PubChem
    MW335.2
    FormulaC16H12Cl2N2O2
    LogP2.4
    IUPAC7-chloro-5-(2-chlorophenyl)-3-hydroxy-1-methyl-3H-1,4-benzodiazepin-2-one
    InChIKeyFJIKWRGCXUCUIG-UHFFFAOYSA-N
    Chemical Class Benzodiazepine
    Psychoactive Class Depressant

    Pharmacology

    DrugBank
    Half-life The terminal phase half life is 11 h . State Solid

    Description

    Lormatazepam is an orally available benzodiazepine used in the UK for the treatment of short-term insomnia . It is marketed by Auden Mckenzie (Pharma Division) in 0.5 and 1 mg tablet formulations.

    Mechanism of Action

    Lormetazepam, as a benzodiazepine, binds to the regulatory site between the α and γ subunits of γ-aminobutryic acid (GABA) A receptors with γ2 and α1, α2, α3, or α5 subunits . This facilitates the opening of the chloride channel allowing chloride ions to flow into the neuron resulting in hyperpolarization. Hyperpolarized neurons require greater simulation to reach their action potential threshold. The general inhibitory effect on neuronal depolarization produces the effects of lormetazepam.

    Pharmacodynamics

    Lormetazepam is a benzodiazepine which reduces central nervous system (CNS) activity . It produces anxiolytic, muscle relaxant, sedative and hypnotic effects. Because it is a short-acting benzodiapine, it does not produce significant sedation after waking.

    Metabolism

    Metabolised to an inactive metabolite via glucuronide conjugation

    Indication

    For the treatment of short-term insomnia

    Toxicity

    PubChem DrugBank

    Benzodiazepines bind nonspecifically to benzodiazepine receptors BNZ1, which mediates sleep, and BNZ2, which affects affects muscle relaxation, anticonvulsant activity, motor coordination, and memory. As benzodiazepine receptors are thought to be coupled to gamma-aminobutyric acid-A (GABAA) receptors, this enhances the effects of GABA by increasing GABA affinity for the GABA receptor.

    Carcinogenicity

    No indication of carcinogenicity to humans (not listed by IARC).

    Toxicity (DrugBank)

    The primary manifestation of overdosage ranges from drowsiness to coma and symptoms may include ataxia, hypotension, hypotonia, respiratory depression which may lead to death . Experimental LD50 values are as follows : Mouse - 780 mg/kg (intraperitoneal), 1790 mg/kg (oral), 10000 mg/kg (subcutaneous). Rat - 6250 mg/kg (intraperitoneal), 10000 mg/kg (oral), 10000 mg/kg (intraperitoneal).

    Effect Profile

    Curated
    Benzodiazepine 7.6

    Strong euphoria and anxiolysis with mild sedation, low cognitive impairment

    Anxiolysis×3
    8
    Sedation / Relaxation×2
    5
    Motor / Cognitive Impairment×1
    1
    Euphoria / Mood Lift×1
    10

    Tolerance & Pharmacokinetics

    drugs.wiki

    Tolerance Decay

    Full tolerance 3d Half tolerance 37d Baseline ~60d
    ← Back to Lormetazepam